___________________________________________________________________________________________________________________________________________________________________________ $CELZ: Massive 1 for 150 Reverse Stock Split of their common shares was implemented on.... Jan 28th, 2020:
(pre reverse split share price was approx .0002 to .0003 per share in early to mid Jan 2020)
Split correct share price as of May 2020 = approx 0.00002 per share (99.9% losses to common shares under current CELZ mgt team)
Quote of SEC 8-K filing:
"Item 3.03 Material Modification to Rights of Security Holders.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
As previously reported, the Board of Directors and stockholders of Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), have approved a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”),at a ratio of 1-for-150 (the “Reverse Stock Split”).
The Reverse Stock Split will become effective pursuant a Certificate of Amendment (the “Certificate”) filed by the Company with the Secretary of State of the State of Nevada on January 28, 2020 pursuant to Nevada Revised Statutes (“NRS”) Sections 78.385 and 78.390. A copy of the Certificate has been filed as Exhibit 3.1 hereto and is incorporated herein by reference."
Creative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells PHOENIX, May 8, 2018
100 Patients Treated For Erectile Dysfunction Utilizing Company's Patented CaverStem® Stem Cell Procedure With Significant Success Rate And No Adverse Effects Reported
General corporate updates and plans for second half of 2019
Jun 20, 2019 7:50 AM EDT
PHOENIX, June 20, 2019 /PRNewswire/ -- Creative Medical Technology Holdings, Inc.
(OTCQB: CELZ), a leading commercial stage biotechnology company focused on Urology, Orthopedics and Neurology using stem cell treatments, today announced business updates and plans for remainder of 2019.
Recent Business Highlights
A Look Ahead (H2 2019 Plans)
- CaverStem® Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men
- Healthcare Professional (HCP) Recruitment/Training ongoing with 5 new facilities coming onboard in the last 60 days and multiple other locations presently being vetted and scheduled for training.
Increasing consumer awareness campaigns utilizing print/digital/radio in local regions where CaverStem® is offered successfully driving patients into clinic
Featured on ABC News as breakthrough technology with potential to help millions of men - many additional requests for media currently being vetted
FemCelz™ Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction
- Soft launch utilizing established CaverStem® clinics proving to be effective commercial strategy
5 additional patients successfully treated in New Mexico within the past 30 days.
StemSpine™ Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease using the patients own bone marrow derived stem cells.
- As previously announced, the StemSpine program is scheduled for a soft launch in the latter part of 2019. Currently the company continues to focus its efforts on commercialization of its lead out technologies CaverStem® and FemCelz™
- The AmnioStem technology is the use of stem cells from amniotic fluid which is considered a drug. This process differs significantly from our other technologies whereupon we use the patients own bone marrow derived stem cells. This requires a an investigational new drug application process through the FDA, of which we are highly familiar. We are moving forward with this program and are pleased with the progress.
- Demonstrate Thought Leadership/Scientific Prowess:
- Submission to scientific peer-reviewed journals to showcase early clinical data
Present at targeted industry conferences
Host webinars utilizing our Scientific Advisory Board
Continuing to implement our electronic registry so that physicians may share information with one another under strict HIPAA compliance.
CaverStem® /FemStem™ Centers of Excellence
- Continue to onboard new CaverStem® and FemCelz™ centers strategic locales around the world
Optimize training program to ensure new HCPs are equipped to succeed
Provide ongoing support to address any questions utilizing peer to peer network
Provide continued marketing in specific locations
- Expand online marketing campaign to create human connection at digital scale
Seek strategic product placement partnerships (i.e. The Doctors)
Develop a comprehensive referral program to turn existing happy clients into evangelists
"We are at an inflection point in our efforts to establish Creative Medical Technology Holdings, Inc. as the pre-eminent leader in unlocking the full potential of stem cells for medical breakthroughs in the areas of Urology, Orthopedics and Neurology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. "We are thrilled by the support of the medical community for our leading CaverStem® procedure and energized by the success stories that are pouring in from around the world from men whose lives have been drastically improved as a direct result of our products. We remain steadfast in our commitment to accelerate adoption of CaverStem® and utilize our existing relationships with HCPs to introduce FemCelz™ to help the growing number of women that experience sexual dysfunction." Dr. Elias Said, MD, FACEP added, "As a medical doctor for over 30 years, rarely have I seen a technology that has the potential to radically improve lives more than CaverStem® and FemStem™. In addition to becoming a leading provider of the technologies out of my Regenerative Medicine Health location in Las Cruces, NM, I am proud to partner with Creative Medical Technology Holdings, Inc.
to serve as a trainer to onboard other HCPs interested in establishing their own practices around the country. Most recently, I had the pleasure of training two locations in the Greater Los Angelesarea." About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition. About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTCQB under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com . Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov
. Creativemedicaltechnology.com Caverstem.com Femcelz.com
Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversing natural aging.
Previous studies by the Company have demonstrated that AmnioStemTM cells secrete factors that are capable of rejuvenating aged cells. By encapsulating the cells outside of the body, so that the cells are in contact with the patient's circulation, the cells are permitted to secrete factors that may reduce aging, without having to inject the cells in the patient.
The concept of using cells that are growing outside of the body as a means of modifying physiological activities has previously been performed and appears feasible. Specifically, similar approaches to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure. A clinical trial demonstrated feasibility of using cell culture of hepatocytes to act as a "liver assist device". These devices are currently in Phase 3 of clinical trials1,2.
The filed patent describes a similar approach to those used in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStemTM amniotic fluid derived stem cells.
"Previous studies from Stanford University3 and Harvard University4 have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effects on organs/tissues of aged mice. Through this patent, we are aiming to recapitulate this effect, in an ethical and technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief Scientific Officer. "What is stunning about the AmnioStemTM stem cell, which was licensed by the Company from the University of California San Diego, is that it possesses many regenerative features but is collected from non-controversial sources."
The AmnioStemTM stem cell is derived from amniotic fluid during the process of amniocentesis. Amniotic fluid is typically considered medical waste. Scientists at University of California San Diego have developed means of extracting and growing stem cells from the amniotic fluid. These stem cells have been published to be capable of treating animal models of numerous diseases including stroke5, heart attack6, liver failure7, colitis8, diabetes9, emphysema10, and kidney injury11. An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making them "universal donor" stem cells.
"The concept of using young blood to stimulate regeneration in aged individuals is attracting much attention in the area of regenerative medicine. I am enthusiastic about the approach being developed by Creative Medical Technology Holdings, which overcomes some of the important roadblocks that prevent implementation of this novel and promising approach," said Amit Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and coinventor of the patent.
"At Creative Medical Technology Holdings we are committed to advancing regenerative medicine to various areas of human suffering. In contrast to other conditions, aging will occur in everyone," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "While the field of anti-aging medicine is filled with various false hopes and hype, we are attempting to address this problem cautiously and methodologically through testing our technology for safety and efficacy.'
"Our goal is to continue to internally develop and patent technology in the regenerative medicine space and to broaden our patent portfolio for future commercialization by the company and/or with other life science companies with complementary technology."
Creative Medical Technology Holdings Forms CaverStem International LLC
Subsidiary to concentrate on International Erectile Dysfunction Market
PHOENIX and LOS ANGELES, June 19, 2018
PHOENIX and LOS ANGELES, June 19, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CaverStem International LLC, a majority owned subsidiary focused on commercializing stem cell therapy for erectile dysfunction to international physicians and their patients.
"Due to the enthusiastic response from international attendees at the American Urological Association conference held in May 2018, we've determined it is in the best interest of the company to form a subsidiary to pursue commercialization with physicians from around the world," said Timothy Warbington President and CEO of Creative Medical Technologies, Inc. and Managing Member of CaverStem International LLC.
Dr. Alexander Gershman, an internationally renowned urologist, lecturer, inventor and Scientific Advisory Board Member at Creative Medical Technology Holdings, Inc., will take on an expanded role with CaverStem International, utilizing not only his vast expertise but also his international relationships in the urology community to expand our physician base. Dr. Gershman is one of the Managers and Members of this subsidiary. "We're excited that Dr. Gershman who was the first physician to treat patients commercially with the CaverStemTM procedure, is taking on this role with the company," Timothy Warbington said further.
"I am pleased to take on this expanded role as a Manager and Member of CaverStem International. As a treating physician I have experienced first hand the safety and efficacy of the CaverStemTM procedure and I'm excited to introduce our technology to my peers in the international urology community. Since beginning to offer the CaverStem™ procedure in December 2017 I have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work," said Dr. Alexander Gershman.
Creative Medical Health Technology Holdings is offering the Caverstem™ technology to selected physicians in the USA, which qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on the procedure go to www.caverstem.com.